Trials / Withdrawn
WithdrawnNCT01787786
Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels
Defining and Predicting the Ideal Infliximab Pharmacokinetic Profile Associated With Treatment Efficacy in Patients With Inflammatory Bowel Disease
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- University of Western Ontario, Canada · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to develop a predictive model that will allow optimized dosing of infliximab for individual patients
Detailed description
The use of pharmacokinetic analyses incorporating relevant determinants of the infliximab serum concentration can be used to develop a predictive model that will allow optimized dosing for individual patients.
Conditions
Timeline
- Primary completion
- 2017-03-01
- Completion
- 2017-09-01
- First posted
- 2013-02-11
- Last updated
- 2015-12-03
Source: ClinicalTrials.gov record NCT01787786. Inclusion in this directory is not an endorsement.